Optimizing outcomes for patients with severe haemophilia A

Haemophilia

Volumn 13, Issue SUPPL.4, 2007, Pages 1-16

  Pipe, S W ^a   Valentino, Leonard A ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; DESMOPRESSIN ACETATE;

ARTHROPATHY; ARTICLE; BREAKTHROUGH BLEEDING; CHILD CARE; CHRONIC PAIN; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE SEVERITY; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; HEMARTHROSIS; HEMOPHILIA A; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JOINT CONTRACTURE; JOINT RADIOGRAPHY; JOINT SWELLING; MULTIPLE CYCLE TREATMENT; PAIN ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; TREATMENT OUTCOME; VASCULAR ACCESS;

ADULT; CATHETERS, INDWELLING; CHILD; COAGULANTS; COSTS AND COST ANALYSIS; FACTOR VIII; HEMARTHROSIS; HEMOPHILIA A; HUMANS; PATIENT TRANSFER; QUALITY OF LIFE; RECURRENCE; REFUSAL TO TREAT; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 34548526103     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01552.x     Document Type: Article

References (97)

1. Pergantou H, Matsinos G, Papadopoulos A, Platokouki H, Aronis S. Comparative study of validity of clinical, X-ray and magnetic resonance imaging scores in evaluation and management of haemophilic arthropathy in children. Haemophilia 2006; 12: 241-7.
2. White GC II, Rosendaal F, Aledort LM et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
3. Carcao MD, Aledort L. Prophylactic factor replacement in hemophilia. Blood Rev 2004; 18: 101-13.
4. Rodriguez-Merchan EC. Pathogenesis, early diagnosis, and prophylaxis for chronic hemophilic synovitis. Clin Orthop Relat Res 1997; 343: 6-11.
5. Silva M, Luck JV Jr, Llinás A. Chronic hemophilic synovitis: The role of radiosynovectomy. Treatment of Hemophilia Monograph Series [No. 33]. Available at: http://www.wfh.org/2/docs/Publications/ Musculoskeletal_Physiotherapy/TOH-33_English_Synovectomy.pdf. Accessed May 19, 2006.
6. DePalma AF. Hemophilic arthropathy. Clin Orthop Relat Res 1967; 52: 145-65.
7. Arnold WD, Hilgartner MW. Hemophilic arthropathy. Current concepts of pathogenesis and management. J Bone Joint Surg Am 1977; 59: 287-305.
8. Aledort LM, Haschmeyer RH, Pettersson H, and the Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med 1994; 236: 391-9.
9. Fischer K, van Hout BA, van der Bom JG, Grobbee DE, van den Berg HM. Association between joint bleeds and Pettersson scores in severe haemophilia. Acta Radiol 2002; 43: 528-32.
10. DiMichele D, Chuansumrit A, London AJ et al. Ethical issues in haemophilia. Haemophilia 2006; 12 (Suppl. 3): 30-35.
11. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Propholaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
12. Molho P, Rolland N, Lebrun T et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group secretariat.haemophilesγch.ap-hop-paris.fr. Haemophilia 2000; 6: 23-32.
13. Blanchette VS. Prophylaxis in hemophilia: A comprehensive prospective. Hematologica 2004; 89 (Suppl. 1): 29-35.
14. Fischer K, van der Bom JG, Mauser-Bunschoten EP et al. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia 2001; 7: 446-52.
15. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
16. van Creveld S. Prophylaxis of joint hemorrhages in hemophilia. Acta Haematol 1971; 45: 120-7.
17. Panicker J, Warrier I, Thomas R, Lusher JM. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003; 9: 272-8.
18. van den Berg HM, Fischer K, Mauser-Bunschoten EP et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 561-5.
19. Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients - a long-term follow-up. J Intern Med 1997; 241: 395-400.
20. Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol 1996; 92: 973-8.
21. Fischer K, van der Bom JG, Molho P et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: A comparison of costs and long-term outcome. Haemophilia 2002; 8: 745-52.
22. Brackmann HH, Eickhoff HJ, Oldenburg J, Hammerstein U. Long-term therapy and on-demand treatment of children and adolescents with severe haemophilia A: 12 years of experience. Haemostasis 1992; 22: 251-8.
23. Butler RB, McClure W, Wulff K. Practice patterns in haemophilia A therapy-a survey of treatment centres in the United States. Haemophilia 2003; 9: 549-54.
24. Geraghty S, Dunkley T, Harrington C et al. Practice patterns in haemophilia A therapy - global progress towards optimal care. Haemophilia 2006; 12: 75-81.
25. Centers for Disease Control and Prevention. Report on the Universal Data Collection Program. 2005; 7: 1-39. Available at http://www.cdc.gov/ ncbddd/hbd/documents/UDC7(1).pdf. Accessed May 23, 2007.
26. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965; 77: 3-132.
27. Nilsson IM, Blomback M, Ramgren O. Haemophilia in Sweden VI. Treatment of haemophilia A with the human antihaemophilic factor preparation (fraction I-0). Acta Med Scand Suppl 1962; 379: 61-110.
28. Antunes SV, Vicari P, Cavalheizro S, Bordin JO. Intracranial haemorrhage among a population of haemophilic patients in Brazil. Haemophilia 2003; 9: 573-7.
29. Shapiro AD, Donfield SM, Lynn HS et al. Defining the impact of hemophilia: The Academic Achievement in Children with Hemophilia Study. Pediatrics 2001; 108: E105.
30. MASAC. Medical and Scientific Advisory Council Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). MASAC Recommendation 170. National Hemophilia Foundation, 2006.
31. Srivastava A, Giangrande P, Poon MC, Chua M, McCraw A, Wiedel J. Guidelines for the management of hemophilia. Available at http://www.wfh.org/2/docs/Publications/Diagnosis_and_Treatment/ Gudelines_Mng_Hemophilia.pdf. Accessed March 6, 2007.
32. Berntorp E, Boulyjenkov V, Brettler D et al. Modern treatment of haemophilia. Bull World Health Organ 1995; 73: 691-701.
33. Stobart K, Iorio A, Wu JK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B (review). The Cochrane Collaboration. Available at http://www.thecochranelibray.com. Accessed February 25, 2007.
34. Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start? - The German experience. Haemophilia 1998; 4: 413-7.
35. Ljung R. Second Workshop of the European Paediatric Network for Haemophilia Management, 17-19 September 1998 in Vitznau/Switzerland. Haemophilia 1999; 5: 286-91.
36. Berntorp E, Astermark J, Bjorkman S et al. Consensus perspectives on prophylactic therapy for haemophilia: Summary statement. Haemophilia 2003; 9 (Suppl. 1): 1-4.
37. Ota S, McLimont M, Carcao MD et al. Definitions for haemophilia prophylaxis and its outcomes: The Canadian consensus study. Haemophilia 2007; 13: 12-20.
38. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980; 149: 153-9.
39. Fijnvandraat K, Peters M, Ten Cate JW. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol 1995; 91: 474-6.
40. van Dijk K, Fischer K, van der Bom JG, Grobbee DE, van den Berg HM. Variability in clinical phenotype of severe haemophilia: The role of the first joint bleed. Haemophilia 2005; 11: 438-43.
41. Barnes C, Lillicrap D, Pazmino-Canizares J et al. Pharmacokinetics of recombinant factor VIII (Kogenate-FS ®) in children and causes of inter-patient pharmacokinetic variability. Haemophilia 2006; 12 (Suppl. 4): 40-49.
42. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-13.
43. van den Berg HM, Dunn A, Fischer K, Blanchette VS. Prevention and treatment of musculoskeletal disease in the haemophilia population: Role of prophylaxis and synovectomy. Haemophilia 2006; 12 (Suppl. 3): 159-68.
44. Fischer K, van der Bom JG, Mauser-Bunschoten EP et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002; 99: 2337-41.
45. Valentino LA. Secondary prophylaxis therapy: What are the benefits, limitations and unknowns? Haemophilia 2004; 10: 147-57.
46. Manco-Johnson MJ, Nuss R, Geraghty S, Funk S, Kilcoyne R. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 1994; 47: 113-7.
47. Liesner RJ. Prophylaxis in haemophilic children. Blood Coagul Fibrinolysis 1997; 8 (Suppl. 1): S7-10.
48. Yee TT, Beeton K, Griffioen A et al. Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia 2002; 8: 76-82.
49. Tagliaferri A, Rivolta GF, Rossetti G, Pattacini C, Gandini G, Franchini M. Experience of secondary prophylaxis in 20 adolescent and adult Italian hemophiliacs. Thromb Haemost 2006; 96: 542-3.
50. Fischer K, Astermark J, van der Bom JG et al. Prophylactic treatment for severe haemophilia: Comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002; 8: 753-60.
51. Feldman BM, Pai M, Rivard GE et al. Tailored prophylaxis in severe hemophilia A: Interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228-36.
52. National Hemophilia Foundation. MASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). Medical and Scientific Advisory Council (MASAC) Recommendation no. 170. 2006.
53. Gilbert MS. Prophylaxis: Musculoskeletal evaluation. Semin Hematol 1993; 30: 3-6.
54. Ware JE. SF-35® health survey update. Available at http://www.sf-36.org/tools/sf36.shtml. Accessed February 8, 2007.
55. Ahnstrom J, Berntorp E, Lindvall K, Bjorkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004; 10: 689-97.
56. Carlsson M, Berntorp E, Bjorkman S, Lindvall K. Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol 1993; 51: 247-52.
57. Berntorp E. Pharmacoeconomics of factor dosing in the haemophilia population. Haemophilia 2006; 12 (Suppl. 4): 70-73.
58. Bjorkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia 2003; 9 (Suppl. 1): 101-8; discussion 9-10.
59. Pettersson H, Gilbert M. Diagnostic Imaging in Hemophilia: Muscuskeletal and Other HemorrhPgic Complications Berlin: Springer-Verlag, 1985: pp. 56-65.
60. Manco-Johnson MJ, Nuss R, Funk S, Murphy J. Joint evaluation instruments for children and adults with haemophilia. Haemophilia 2000; 6: 649-57.
61. Kilcoyne RF, Nuss R. Radiological assessment of haemophilic arthropathy with emphasis on MRI findings. Haemophilia 2003; 9 (Suppl. 1): 57-63; discussion -4.
62. Scalone L, Mantovani LG, Mannucci PM, Gringeri A. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006; 12: 154-62.
63. Bradley CS, Bullinger M, McCusker PJ, Wakefield CD, Blanchette VS, Young NL. Comparing two measures of quality of life for children with haemophilia: The CHO-KLAT and the Haemo-QoL. Haemophilia 2006; 12: 643-53.
64. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7: 392-6.
65. Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia 2004; 10: 134-46.
66. Blanchette VS, McCready M, Achonu C, Abdolell M, Rivard G, Manco-Johnson MJ. A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia 2003; 9 (Suppl. 1): 19-26.
67. Tarantino MD, Lail A, Donfield SM et al. Surveillance of infectious complications associated with central venous access devices in children with haemophilia. Haemophilia 2003; 9: 588-92.
68. Ewenstein BM, Valentino LA, Journeycake JM et al. Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia 2004; 10: 629-48.
69. Carcao MD, Connolly BL, Chait P et al. Central venous catheter-related thrombosis presenting as superior vena cava syndrome in a haemophilic patient with inhibitors. Haemophilia 2003; 9: 578-83.
70. Petrini P. How to start prophylaxis. Haemophilia 2003; 9 (Suppl. 1): 83-85; discussion 6-7.
71. National Institute of Diabetes and Digestive and Kidney Diseases. Vascular access for hemodialysis. NIH Publication No. 05-4554. January 2005. Available at http://kidney.niddk.nih.gov/kudiseases/pubs/pdf/ vascularaccess.pdf. Accessed January 17, 2007.
72. Santagostino E, Gringeri A, Berardinelli L, Beretta C, Muca-Perja M, Mannucci PM. Long-term safety and feasibility of arteriovenous fistulae as vascular accesses in children with haemophilia: A prospective study. Br J Haematol 2003; 123: 502-6.
73. McCarthy WJ, Valentino LA, Bonilla AS et al. Arteriovenous fistula for long-term venous access for boys with hemophilia. J Vasc Surg 2007; 45: 986-90.
74. Steen Carlsson K, Hojgard S, Glomstein A et al. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 2003; 9: 555-66.
75. Bohn RL, Avorn J, Glynn RJ, Choodnovskiy I, Haschemeyer R, Aledort LM. Prophylactic use of factor VIII: An economic evaluation. Thromb Haemost 1998; 79: 932-7.
76. Ullman M, Hoots WK. Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors. Haemophilia 2006; 12 (Suppl. 6): 74-80.
77. Fischer K, Van Den Berg M. Prophylaxis for severe haemophilia: Clinical and economical issues. Haemophilia 2003; 9: 376-81.
78. Astermark J. When to start and when to stop primary prophylaxis in patients with severe haemophilia. Haemophilia 2003; 9 (Suppl. 1): 32-6; discussion 7.
79. Chapman JR. Compliance: The patient, the doctor, and the medication ? Transplantation 2004; 77: 782-6.
80. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-97.
81. Lindvall K, Colstrup L, Wollter IM et al. Compliance with treatment and understanding of own disease in patients with severe and moderate haemophilia. Haemophilia 2006; 12: 47-51.
82. Evatt BL. The tragic history of AIDS in the hemophilia population, 1982-1984. J Thromb Haemost 2006; 4: 2295-301.
83. Chorba TL, Holman RC, Clarke MJ, Evatt BL. Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States. Am J Hematol 2001; 66: 229-40.
84. Sieger L, Aledort L. Inhibitor challenges in the paediatric setting. Haemophilia 2006; 12: 106-7.
85. Hooiveld MJ, Roosendaal G, Vianen ME, van den Berg HM, Bijlsma JW, Lafeber FP. Immature articular cartilage is more susceptible to blood-induced damage than mature articular cartilage: An in vivo animal study. Arthritis Rheum 2003; 48: 396-403.
86. van Dijk K, Fischer K, van der Bom JG, Scheibel E, Ingerslev J, van den Berg HM. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol 2005; 130: 107-12.
87. Fischer K, van der Bom JG, Prejs R et al. Discontinuation of prophylactic therapy in severe haemophilia: Incidence and effects on outcome. Haemophilia 2001; 7: 544-50.
88. Loverin JA, Mensah P, Nokes TJC. Limited prophylaxis in adults with severe haemophilia: A pilot study. Haemophilia 2000; 6: 275.
89. Ewenstein BM. Von Willebrand's disease. Annu Rev Med 1997; 48: 525-42.
90. Luchtman-Jones L, Valentino LA, Manno C. Considerations in the evaluation of haemophilia patients for short-term prophylactic therapy: a paediatric and adult case study. Haemophilia 2006; 12: 82-86.
91. Tarantino MD, Collins PW, Hay CR et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/ albumin-free method: Pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004; 10: 428-37.
92. Abshire TC, Brackmann HH, Scharrer I et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy-International Kogenate-FS Study Group. Thromb Haemost 2000; 83: 811-6.
93. Lusher JM, Lee CA, Kessler CM, Bedrosian CL. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 38-49.
94. Stieltjes N, Calvez T, Demiguel V et al. Intracranial haemorrhages in French haemophilia patients (1991-2001): Clinical presentation, management and prognosis factors for death. Haemophilia 2005; 11: 452-8.
95. Kulkarni R, Lusher J. Perinatal management of newborns with haemophilia. Br J Haematol 2001; 112: 264-74.
96. Balkan C, Kavakli K, Karapinar D. Iliopsoas haemorrhage in patients with haemophilia: Results from one centre. Haemophilia 2005; 11: 463-7.
97. Bolton-Maggs PH, Stobart K, Smyth RL. Evidence-based treatment of haemophilia. Haemophilia 2004; 10 (Suppl. 4): 20-24.